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Introduction 50
Extended-spectrum beta-lactamases (ESBLs) are enzymes classified as Class 51
A in the Ambler classification of beta-lactams,(1) and are responsible for 52 multi-resistance to most beta-lactam antibiotics including penicillins, cephalosporins, 53 and monobactams. The global increase in ESBL-producing pathogens, particularly 54
Escherichia coli and Klebsiella pneumoniae, is a major clinical concern. The current 55 effective therapeutic option for severe infections caused by ESBL-producing pathogens 56 is carbapenems.(2, 3) However, it is necessary to develop other therapeutic options 57 because of the emergence and global spread of carbapenemase-producing 58
Enterobacteriaceae. 59
Recently, combination agents consisting of a cephalosporin and 60 beta-lactamase inhibitor, such as ceftazidime-avibactam and ceftolozane-tazobactam, 61 have been developed. Ceftolozane-tazobactam showed good activity against most 62 ESBL-producing E. coli isolates, but lower activity against ESBL-producing K. 63 pneumoniae isolates.(4, 5) By contrast, the addition of avibactam significantly increased 64 the activity of ceftazidime against ESBL-producing pathogens including K. 65 pneumoniae.(6) OP0595 (RG6080) is a novel diazobicyclooctane that, similar to 66 avibactam, inhibits class A and C serine beta-lactamases. In addition to the inhibition of 67 beta-lactamases, OP0595 showed antimicrobial activity by inhibiting penicillin binding 68 protein 2 (PBP2) and enhanced the antimicrobial activity of the beta-lactams that bind 69 to PBP3. (7, 8) The combination of OP0595 and beta-lactams showed good in vitro 70 activity against ESBL-, AmpC-, and carbapenemase-, including OXA-48 class 71 beta-lactamases, producing pathogens.(7-9) Additionally, the combination of OP0595 72 and cefepime (FEP) showed a dose-dependent effect in a neutropenic murine thighinfection model.(9) However, the effect of the combination therapy against severe 74 infections, such as pneumonia or bacteraemia, remains unknown. 75
In this study, we investigated the efficacy and pharmacokinetics of the 76 combination therapy of OP0595 and FEP in a mouse model of pneumonia caused by 77 ESBL-producing K. pneumoniae. 78
Bacterial strains 81
The K. pneumoniae strain used in this study was the KEN-11 strain, a clinical 82 isolate obtained at the Nagasaki University Hospital.(10) The KEN-11 strain is positive 83 for SHV and CTX-M-9-type ESBLs and showed positive results in the string test.(10) 84
The bacteria were stored at -80°C in a Microbank® bead preservation system (Pro-Lab 85 Diagnostics, Ontario, CA) until use. 86
87

Antimicrobial agents 88
OP0595 was supplied by Meiji Seika Pharma Co., Ltd. (Tokyo, Japan). 89
Cefepime dihydrochloride hydrate was purchased from Bristol-Myers Squibb Company 90 (Tokyo, Japan). 91
92
Animals 93
We purchased specific pathogen-free BALB/c male mice (6-to 7-week-old) 94 from Japan SLC, Inc. (Shizuoka, Japan). The mice were housed in a pathogen-free 95 environment and received sterile food and water at the Biomedical Research Centre of 96 Nagasaki University. 97
98
Ethics 99
All the experimental protocols used in this study were approved by the Ethics 100
Review Committee for Animal Experimentation (approval number 1503101199). 
Pharmacokinetic studies 111
The Mice were infected with the bacterial suspension intra-tracheally (0.05 112 mL; 1 × 10 6 CFU/mouse). At 12 hours post inoculation, the mice were treated with 100 113 mg/kg of FEP and 20 or 100 mg/kg of OP0595, and were then sacrificed by cervical 114 dislocation at 5, 15, 30, 45, 60, 90, 120 , and 180 minutes post administration. Blood 115 was collected via a right ventricular puncture using heparin-coated syringes. Four mice 116 were used for each group. The blood samples were centrifuged and the isolated plasma 117 samples were stored at -80°C until use. 118
The concentration of FEP and OP0595 in plasma was measured using a liquid 119 chromatograph (ACQUITY UPLC System, Waters, Milford, MA, United States) 120 coupled with a tandem mass spectrometer (QTRAP 5500, AB Sciex, Tokyo, Japan). For 121 pharmacokinetic analysis, WinNonlin Professional Ver. 6.3 (Certara) was used. 122
Plasma concentration was analysed using a non-compartmental model to 123 calculate the elimination half-life (t1/2), apparent volume of distribution (V/F), area 124 under the plasma concentration-time curve from 0 to infinity (AUC0-inf), and total body 125 clearance (CL). 
Bacteriological examinations 143
Mice were sacrificed from each group at 36 hours post inoculation. 144 Subsequently, they were dissected under aseptic conditions. Blood was collected via a 145 right ventricular puncture using heparin-coated syringes. The lungs were removed, 146 suspended in 1 mL of normal saline, and homogenized with a homogenizer (AS One 147
Co., Osaka, Japan). The lungs were then cultured and the serially diluted blood samples 148 were spread onto the Mueller-Hinton II agar plates. After overnight incubation at 37°C, 149 the number of visible colonies in the plates was evaluated. The lowest level of 150 detectable bacterial count was 1× 10 2 CFU/mL. 151 A statistical software package (StatMate V; ATMS Co., Ltd., Tokyo, Japan) 154 was used for all the statistical comparisons and the survival rates were calculated using 155 the Kaplan-Meier method. The survival analysis was performed using the log-rank test 156 and the data were expressed as the mean and standard deviation (SD). In the graph of 157 the bacterial count in the lungs and the blood, the data were depicted by a 158 box-and-whisker plot and the differences between the groups were analysed using a 159 one-way analysis of variance with Tukey's post-hoc test. All the tests of significance 160
were two-tailed and the alpha level for denoting statistical significance was set at < 161
162
Results 165
MICs of the antimicrobial agents against KEN-11 166
The MICs of FEP and OP0595 against the KEN-11 strain were 8 and 4 mg/L, 167
respectively. The MIC of FEP against the bacterial strain markedly improved in 168 combination with OP0595 (Table 1) . 169
170
Pharmacokinetics of the antimicrobial agents 171
The plasma concentration profiles and calculated pharmacokinetic parameters 172 of FEP and OP0595 are presented in Fig. 1 and Table 2 . The concentration of OP0595 173 in plasma with 20 mg/kg of OP0595 was significantly lower than that with 100 mg/kg 174 of OP0595 at 5, 15, 30, 45, 60 and 180 minutes post treatment (P < 0.05) ( mg/kg of OP0595 administered twice a day were 27.1, 27.7 and 27.7%, respectively. 183
Therapeutic effects of the antimicrobial agents on survival rate 184
Based on the results of pharmacokinetic studies, we decided the doses of 185 OP0595 and FEP. Since we mainly investigated the effect of OP0595, such as inhibition 186 of beta-lactamases and enhance effect of the antimicrobial activity of the beta-lactams 187 that bind to PBP3, the mice were administered saline (control), 100 mg/kg of FEP, 20
In the survival study, the mice were treated using the prescribed methods until 190 108 hours post inoculation and the survival rates were observed until 120 hours post 191 inoculation (n = 7 in each group). As shown in Fig. 3A , the survival rates were 192 significantly higher in the combination treatment group than that in the other groups (P 193 < 0.001). 194
In the bacteriological examinations, the mice were sacrificed 36 hours post 195 inoculation (n = 6 in each group). The number of bacteria in the lungs in the control, 196 OP0595, FEP, and combination treatment groups was 8. 65 ± 0.58, 8.35 ± 0.40, 8.94 ± 197 0.48, and 4.47 ± 0.99 log10 CFU/mL, respectively (Fig. 3B) . The number of bacteria in 198 the lungs was significantly lower in the combination treatment group than that in the 199 other groups (P < 0.001). The number of bacteria in the blood in the control, OP0595, 200 FEP, and combination treatment groups was 7.41 ± 0.93, 6.44 ± 0.71, 7.07 ± 1.20, and 201 4.49 ± 1.29 log10 CFU/mL, respectively (Fig. 3C) . The number of bacteria in the blood 202 was significantly lower in the combination treatment group than that in the other groups 203 (P < 0.001 versus the control; P < 0.05, versus the OP0595 treatment group; P < 0.01, 204 versus the FEP treatment group). 205 206
Effects of the combination therapy that depended on the doses of FEP 207
Twelve hours post inoculation, the mice were treated twice a day with saline 208 (control), or 4, 20, or 100 mg/kg of FEP in combination with 20 mg/kg of OP0595 until 209 108 hours post inoculation. In the survival study, the survival rates were observed until 210 120 hours post inoculation (n = 9 in each group). As shown in Fig. 4A , the survival rates 211 were significantly higher in the 100 mg/kg of FEP treatment group than that in the other 212 groups (P < 0.001). The survival rates in the 4 and 20 mg/kg of FEP treatment groupswere significantly higher than that in the control group (P < 0.05, 4 mg/kg of FEP and P 214 < 0.01, 20 mg/kg). 215
In the bacteriological examinations, the mice were sacrificed 36 hours post 216 inoculation (n = 4, in each groups). The number of bacteria in the lungs in the control 217 group and the 4, 20, and 100 mg/kg of FEP with OP0595 treatment groups was 9.42 ± 218 0.35, 7.46 ± 0.24, 6.53 ± 0.80, and 4.38 ± 0.69 log10 CFU/mL, respectively (Fig. 4B) . 219
The number of bacteria in the lungs was significantly lower in the 100 mg/kg of FEP 220 with OP0595 treatment group than that in the other groups (P < 0.001). The number of 221 bacteria in the lungs was significantly lower in the 4 and 20 mg/kg of FEP with OP0595 222 treatment groups than that in the control group (P < 0.001). The number of bacteria in 223 the blood in the control, 4, 20, and 100 mg/kg of FEP with OP0595 was 8.14 ± 0.42, 224
7.17 ± 0.65, 5.46 ± 1.05, and 2.96 ± 0.68 log10 CFU/mL, respectively (Fig. 4C) . The 225 number of bacteria in the blood was significantly lower in the 100 mg/kg of FEP with 226 OP0595 treatment group, than that in the other groups (P < 0.001). The number of 227 bacteria in the blood was significantly lower in the 20 mg/kg of FEP with OP0595 228 treatment group than that in the control group (P < 0.001). 229
Discussion 232
The combination therapy of OP0595 and FEP showed good in vivo activity 233 against ESBL-producing K. pneumoniae in the mouse model. K. pneumoniae often 234 colonizes at the human digestive tract and nasopharynx,(13) and has been one of the 235 major causes of both community and nosocomial pneumonia. (14) When bacteraemia is 236 complicated with pneumonia, the mortality rate of patients with K. pneumoniae 237 infection is 2-fold higher than that of patients with S. pnuemoniae infection. (15) In 238 addition, the proportion of drug-resistant K. pneumoniae ESBL-producers is relatively 239 high, and the use of appropriate therapy is independently associated with lower 240 mortality.(2) Therefore, there is a need to develop a novel agent including OP0595 241 against ESBL-producing K. pneumoniae. 242
In the antimicrobial susceptibility test, the MIC of OP0595 against the 243 KEN-11 strain was 4 mg/L, which was lower than that of FEP. A previous study 244 reported that OP0595 directly inhibits the growth of many Enterobacteriaceae strains at 245 concentrations of 1-8 mg/L by inhibiting PBP2, and in some strains, the MIC of 246 OP0595 was lower than that of beta-lactams, such as piperacillin, FEP, and 247 ceftazidime.(8) However, in the mouse model of pneumonia caused by K. pneumonia, 248 the mice were treated with 20 mg/kg of OP0595, and monotherapy of OP0595 did not 249 improve survival or decrease the number of bacteria in the lung and blood (Fig. 3) . 250
Hence, we consider that the effect of OP0595 in combination therapy did not depend on 251 the direct antimicrobial activity of OP0595 against the KEN-11 strain. 252 OP0595 is a novel diazobicyclooctane that, similar to avibactam, inhibits 253 class A and C serine beta-lactamases. In the previous study, the IC50 values of OP0595 254 for the class A and C beta-lactamases were similar to or slight higher than those of 255 avibactam.(8) OP0595 also improved the MICs of beta-lactams in a dose-dependentmarkedly improved in combination with 0.5, 1.0, and 2.0 mg/L of OP0595 (Table 1) . 258
Additionally, in the mouse model, the effects of combination therapy of OP0595 and 259 FEP depended on the dose of FEP (Fig. 4) . From these results, the function of OP0595 260 in the combination therapy seems to be as a beta-lactamase inhibitor. 261
However, this does not explain the dose-dependent in vivo effects since 262 the %TAM of 4, 20 and 100 mg/kg of FEP in combination with 20 mg/kg of OP0595 263 were almost the same (Fig. 2) . If the in vivo effect depended on the inhibitory activity 264 of OP0595 against beta-lactamase, then, the %TAM of FEP would increase according to 265 the FEP dose. Moreover, the %TAM of FEP in combination with OP0595 was much 266 lower than the effective %TAM in the previous study. The survival rates were observed until 120 hours after inoculation (n = 7 in each group). * The survival rate in the combination treatment group was significantly higher than the other treatment groups (P < 0.001). Thirty-six hours post inoculation, the mice were sacrificed, and the number of bacteria in the lungs (B) and the blood (C) were analysed (n = 6 in each groups). Box-and-whisker plots show the range and median of the number of bacteria. The number of bacteria in the lungs significantly decreased in the combination therapy group, compared with the other groups (P < 0.001). The number of bacteria in the blood significantly decreased in the combination therapy group, compared with the other groups (P < 0.001, versus the control; P < 0.05, versus the OP0595 treatment group; P < 0.01, versus the FEP treatment group). (A) The survival rates were observed until 120 hours after inoculation (n = 9 in each group). The survival rate in the 100 mg/kg of FEP treatment group was significantly higher than the other treatment groups (*P < 0.001). The survival rates in the 4 and 20 mg/kg of FEP treatment group were significantly higher than that in the control ( † P < 0.05, 4 mg/kg of FEP and P < 0.01, 20 mg/kg of FEP, respectively). Thirty-six hours post inoculation, the mice were sacrificed, and the number of bacteria in the lungs (B) and the blood (C) were analysed (n = 4 in each groups). The number of bacteria in the lungs and blood were significantly lower in the 100 mg/kg of FEP, compared with the other groups (P < 0.001). The number of bacteria in the lungs was significantly decreased in the 4 and 20 mg/kg treatment group, compared with the control ( § P < 0.001). The number of bacteria in the blood was significantly lower in the 20 mg/kg of FEP treatment group compared with the control ( ¶ P < 0.001). 
